Linked Life Data

3925886

Source:http://linkedlifedata.com/resource/pubmed/id/3925886

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
1985-8-16
pubmed:abstractText
A phase II study of UFT, a mixture of futraful and uracil in a rate of 1:4, was performed for prostatic cancer in 5 cooperative institutions. UFT was orally administered at a daily dose of 600 mg (t.i.d.) for 4 weeks. Twenty-two patients treated with UFT were evaluated according to Koyama-Saito's criteria. Tumor staging determined by transrectal ultrasonography and other methods revealed stage B in 4 patients, stage C in 7, and stage D in 11. The overall response rate was 18.2%. Complete response was obtained in 1 patient with stage B disease, partial response in 3, minor response in 1, no change in 15, and progressive disease in 2. With respect to toxicity, anorexia was observed in 9 patients, nausea and vomiting in 8, stomatitis in 4, and diarrhea in 3. White blood cell count was less than 3,000 cells per mm3 in 1 patient, and in another case, hepatic function disorder was observed. From the results obtained, the use of UFT is TS considered desirable for prostatic cancer.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1440-4
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1985
pubmed:articleTitle
[Clinical effect of UFT on prostatic cancer].
pubmed:publicationType
Journal Article, English Abstract, Case Reports